An item on Vical Inc. in the ASCO roundup section of the May 20, 2002, issue of BioWorld Today, should have identified the interim results from a Vical presentation on its Allovectin-7 cancer vaccine program as being from a Phase II registration trial. That item should have been separated from a recruitment update in a high-dose Phase II trial.

A story in the May 22, 2002, issue of BioWorld Today should have said that the head-to-head study of Amgen Inc.'s Aranesp compared to Johnson & Johnson's Procrit involved 122 patients and lasted 12 weeks.

Editor's Note: The corrections have been made in BioWorld Online.

No Comments